

# **MEDICAL LABORATORY EVALUATION**

## **PARTICIPANT SUMMARY**

# **2 • 0 • 0 • 7**

**Please see the corresponding US participant summary for any statistics not represented in this supplement.**



Total Commitment to Education and Service  
Provided by ACP Services, Inc.

**International Data Supplement  
MLE – M2**

# Table of Contents

<b>2007 Evaluation Criteria</b> .....	<b>3</b>
---------------------------------------	----------

## **Coagulation**

<b>Prothrombin Time</b> .....	<b>4</b>
International Normalized Ratio (INR) .....	6
<b>Activated Partial Thromboplastin Time</b> .....	<b>8</b>
<b>Fibrinogen</b> .....	<b>9</b>

## **Urinalysis**

<b>Urinalysis Dipstick</b> .....	<b>10</b>
Specific Gravity .....	10
pH .....	10
Protein .....	11
Glucose or Reducing Substance .....	11
Ketones.....	12
Bilirubin .....	12
Urobilinogen.....	13
Blood or Hemoglobin .....	13
Leukocyte Esterase .....	14
Nitrite .....	14
Microalbumin (Dipstick Only) .....	15
<b>Urine hcG</b> .....	<b>15</b>

## **Microbiology**

<b>Antimicrobial Susceptibility Testing</b> .....	<b>16</b>
<b>Parasitology (PA Specimens)</b> .....	<b>17</b>
<b>Parasitology (FP Specimens)</b> .....	<b>18</b>

## **Immunology**

<b>Syphilis Serology</b> .....	<b>19</b>
VDRL Slide .....	19
VDRL Slide (Titer).....	20
MHA-TP .....	20
FTA-ABS.....	20
RPR .....	21
RPR (Titer).....	22

<b>Viral Markers</b> .....	<b>23</b>
Anti-HBc.....	23
Anti-HIV .....	24
HAV .....	25
HBeAg .....	26
HBsAb.....	27
HBsAg.....	28
HCV .....	29

## **Chemistry**

<b>Blood Gases</b> .....	<b>30</b>
--------------------------	-----------

## 2007 Evaluation Criteria

The evaluation criteria used in the 2007 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	$\pm$ 15 percent
Calcium, Ionized	$\pm$ 3 SD
Chloride	$\pm$ 5%
Fibrinogen	$\pm$ 20 percent
International Normalized Ratio	$\pm$ 3 SD
pCO <sub>2</sub>	$\pm$ 5 mmHg or 8% *
pH	$\pm$ 0.04
pO <sub>2</sub>	$\pm$ 3 SD
Potassium	$\pm$ 0.5 mmol/L
Prothrombin Time	$\pm$ 15 percent
Sodium	$\pm$ 4.0 mmol/L
Specific Gravity	$\pm$ 0.010

\*Whichever is greater



**PROTHROMBIN TIME (seconds)**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Specimen CG-10</u>			<u>Median</u>
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	
All Method	142	12.92	1.57	12.2	12.8
bioMerieux Simplastin Excel S					
bioMerieux Thrombolyzer Compact X/XR	5	16.00	0.60	3.8	15.7
bioMerieux Thrombotimer	10	15.04	0.85	5.6	15.1
All Coagulation Instruments	24	15.21	0.86	5.7	15.3
Dade Innovin					
Sysmex CA-1000/1500	5	11.04	0.30	2.7	10.9
Sysmex CA-500	6	10.63	0.67	6.3	10.9
All Coagulation Instruments	15	10.97	0.57	5.2	10.9
Dade Thromborel S					
Sysmex CA-1000/1500	5	11.76	0.47	4.0	11.7
Sysmex CA-500	9	11.36	0.71	6.2	11.2
All Coagulation Instruments	22	11.97	0.92	7.7	12.1
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	11	13.14	0.13	1.0	13.1
All Coagulation Instruments	12	13.14	0.12	0.9	13.1
IL TEST PT-FIB HS					
IL ACL, all models	6	12.73	0.25	2.0	12.8
IL TEST PT-FIB Recombinant					
IL ACL, all models	29	12.27	0.54	4.4	12.0
Sysmex HemoStat Thromboplastin - SI					
All Coagulation Instruments	6	13.15	1.10	8.4	13.2
Wiener Lab Soluplastin					
Tilt Tube	6	12.82	0.49	3.8	12.9
All Coagulation Instruments	8	12.66	0.53	4.2	12.8



**PROTHROMBIN TIME–INTERNATIONAL NORMALIZED RATIO (INR)**

**Specimen CG-10**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	135	1.04	0.10	9.4	1.0
bioMerieux Simplastin Excel S					
bioMerieux Thrombolyzer	5	1.16	0.05	4.7	1.2
Compact X/XR					
bioMerieux Thrombotimer	10	1.04	0.05	5.0	1.0
All Coagulation Instruments	25	1.07	0.08	7.9	1.1
Dade Innovin					
Sysmex CA-1000/1500	5	1.06	0.05	5.2	1.1
Sysmex CA-500	6	1.02	0.12	11.5	1.0
All Coagulation Instruments	15	1.02	0.09	9.2	1.0
Dade Thromborel S					
Sysmex CA-500	9	0.96	0.05	5.5	1.0
All Coagulation Instruments	21	0.99	0.08	8.4	1.0
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	11	1.00	0	0	1.0
All Coagulation Instruments	13	1.00	0.04	4.1	1.0
IL TEST PT-FIB HS					
IL ACL, all models	6	0.98	0.08	7.7	1.0
IL TEST PT-FIB Recombinant					
IL ACL, all models	31	1.14	0.14	11.9	1.1
Sysmex HemoStat					
Thromboplastin - SI					
All Coagulation Instruments	6	1.02	0.10	9.7	1.1
Wiener Lab Soluplastin					
Tilt Tube	6	1.00	0.15	15.5	1.1
All Coagulation Instruments	8	0.99	0.16	15.7	1.1



**ACTIVATED PARTIAL THROMBOPLASTIN (seconds)****Specimen CG-10**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	126	28.1	3.6	12.6	28
bioMerieux autoAPTT Reagent					
bioMerieux Thrombotimer	10	29.4	3.0	10.2	29
All Coagulation Instruments	20	29.0	3.4	11.7	28
Dade Actin FS					
All Coagulation Instruments	9	27.4	1.9	7.1	27
Dade Actin FSL					
Sysmex CA-1000/1500	5	26.2	0.8	3.2	26
Sysmex CA-500	8	25.8	1.0	4.0	26
All Coagulation Instruments	17	26.1	1.3	4.9	26
Dade Actin					
All Coagulation Instruments	11	24.1	3.1	12.8	24
IL TEST APTT-SP					
IL ACL, all models	35	28.7	1.7	6.0	28
All Coagulation Instruments	39	28.9	2.2	7.6	28
Sysmex HemoStat aPTT - EL					
All Coagulation Instruments	11	28.1	2.5	8.9	27

**FIBRINOGEN (mg/dL)****Specimen CG-6****Specimen CG-7**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	67	203.7	44.1	21.6	195	66	295.2	54.0	18.3	293
Dade Fibrinogen Set										
Sysmex CA-1000/1500	5	237.2	37.7	15.9	243	5	278.4	38.3	13.8	272
Sysmex CA-500	7	256.9	12.6	4.9	258	7	265.7	20.5	7.7	262
All Coagulation Instruments	17	255.8	29.7	11.6	260	17	267.5	33.6	12.6	262
IL TEST PT Fibrinogen										
IL ACL, all models	7	175.9	12.9	7.4	175	6	323.2	47.7	14.8	324
All Coagulation Instruments	8	176.2	12.0	6.8	179	7	323.6	43.6	13.5	324
IL TEST PT-FIB HS										
IL ACL, all models	5	162.4	21.2	13.0	163	5	393.6	47.8	12.1	401
IL TEST PT-FIB Recombinant										
IL ACL, all models	16	174.8	18.1	10.3	174	16	304.7	25.6	8.4	317
Sysmex HemoStat Fibrinogen										
All Coagulation Instruments	5	199.0	24.0	12.1	212	6	265.0	35.0	13.2	279

**Specimen CG-8****Specimen CG-9**

All Method	65	179.8	21.1	11.8	180	70	313.4	46.1	14.7	314
Dade Fibrinogen Set										
Sysmex CA-1000/1500	5	169.4	26.8	15.8	164	5	284.2	31.3	11.0	280
Sysmex CA-500	7	168.0	9.0	5.4	168	8	280.1	25.5	9.1	284
All Coagulation Instruments	17	170.5	18.7	11.0	166	19	281.4	28.3	10.0	280
IL TEST PT Fibrinogen										
IL ACL, all models	7	180.7	21.1	11.7	181	8	353.1	51.1	14.5	353
All Coagulation Instruments	8	184.2	22.0	11.9	184	9	354.3	47.9	13.5	353
IL TEST PT-FIB HS										
IL ACL, all models	5	181.2	19.9	11.0	186	5	352.4	44.1	12.5	364
IL TEST PT-FIB Recombinant										
IL ACL, all models	14	185.2	19.7	10.6	187	17	332.5	33.6	10.1	339
Sysmex HemoStat Fibrinogen										
All Coagulation Instruments	6	172.3	21.0	12.2	173	6	275.7	35.0	12.7	285

## FIBRINOGEN (mg/dL)

### Specimen CG-10

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	66	420.3	48.3	11.5	419
Dade Fibrinogen Set					
Sysmex CA-1000/1500	5	387.0	49.5	12.8	400
Sysmex CA-500	7	414.7	21.5	5.2	409
All Coagulation Instruments	18	409.0	42.0	10.3	409
IL TEST PT Fibrinogen					
IL ACL, all models	6	431.2	57.5	13.3	408
All Coagulation Instruments	7	429.3	52.7	12.3	408
IL TEST PT-FIB HS					
IL ACL, all models	5	435.8	23.6	5.4	449
IL TEST PT-FIB Recombinant					
IL ACL, all models	16	407.6	46.0	11.3	407
Sysmex HemoStat Fibrinogen					
All Coagulation Instruments	5	457.8	54.8	12.0	456

## Urinalysis

### URINALYSIS DIPSTICK–SPECIFIC GRAVITY

#### Specimen UA-2

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Refractive Index Methods	5	1.0240	0.0022	0.2	1.025
All Method	129	1.0124	0.0067	0.7	1.010
Arkray PocketChem UA	5	1.0170	0.0076	0.7	1.015
Bayer Clinitek 500	18	1.0106	0.0015	0.2	1.010
Bayer Clinitek Atlas	5	1.0240	0.0022	0.2	1.025
Bayer Reagent Strips	5	1.0070	0.0027	0.3	1.005
Roche (BMC) Chemstrips	31	1.0131	0.0060	0.6	1.010
Roche Urisys	13	1.0157	0.0081	0.8	1.015
UriScan Reagent Strips	13	1.0138	0.0041	0.4	1.015

### URINALYSIS DIPSTICK–pH

#### Specimen UA-2

#### Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHODS	-	-	-	-	-	-	1	56	46	36	1
Arkray Aution Jet	-	-	-	-	-	-	-	1	2	-	-
Arkray Aution Sticks	-	-	-	-	-	-	-	4	-	1	-
Arkray PocketChem UA	-	-	-	-	-	-	-	1	3	1	-
Bayer Clinitek 50	-	-	-	-	-	-	-	1	2	-	-
Bayer Clinitek 500	-	-	-	-	-	-	-	-	22	1	-
Bayer Clinitek Atlas	-	-	-	-	-	-	-	1	4	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	-	2	-	-
Bayer Reagent Strips	-	-	-	-	-	-	-	1	4	-	-
BioScan Reagent Strips	-	-	-	-	-	-	-	-	-	1	-
Quidel QuickVue UrinChek	-	-	-	-	-	-	-	-	-	1	-
Roche (BMC) Chemstrips	-	-	-	-	-	-	-	16	2	13	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	-	2	-	1	-
Roche (BMC) Mini UA	-	-	-	-	-	-	-	2	-	-	-
Roche Miditron	-	-	-	-	-	-	-	1	-	1	-
Roche Urisys	-	-	-	-	-	-	-	6	-	8	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	-	4	-	-	-
UriScan Reagent Strips	-	-	-	-	-	-	-	9	4	1	-

**URINALYSIS DIPSTICK–PROTEIN QUALITATIVE**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHODS	1	-	1	105	31	-
Arkray Aution Jet	-	-	-	3	-	-
Arkray Aution Sticks	-	-	-	4	1	-
Arkray PocketChem UA	-	-	-	5	-	-
Bayer Clinitek 50	-	-	-	-	3	-
Bayer Clinitek 500	-	-	-	14	9	-
Bayer Clinitek Atlas	-	-	-	3	2	-
Bayer Clinitek Status	-	-	-	-	2	-
Bayer Reagent Strips	-	-	-	2	3	-
BioScan Reagent Strips	-	-	-	1	-	-
Quidel QuickVue UrinChek	-	-	-	1	-	-
Roche (BMC) Chemstrips	-	-	-	26	4	-
Roche (BMC) Criterion Analyzer	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	2	-	-
Roche Miditron	-	-	-	1	1	-
Roche Urisys	1	-	-	9	4	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	4	-	-
UriScan Reagent Strips	-	-	-	12	2	-

**URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>&gt;1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHODS	3	3	1	20	26	67	16	3
Arkray Aution Jet	-	-	-	-	-	-	1	2
Arkray Aution Sticks	-	-	-	-	2	3	-	-
Arkray PocketChem UA	-	-	-	-	2	1	2	-
Bayer Clinitek 50	-	-	-	1	2	-	-	-
Bayer Clinitek 500	1	-	-	11	10	-	1	-
Bayer Clinitek Atlas	-	-	-	2	2	-	1	-
Bayer Clinitek Status	-	1	-	1	-	-	-	-
Bayer Reagent Strips	-	-	-	1	1	1	1	1
BioScan Reagent Strips	-	-	-	-	-	1	-	-
Quidel QuickVue UrinChek	-	-	-	-	-	-	1	-
Roche (BMC) Chemstrips	-	-	1	1	-	28	1	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	-	-	2	-	-
Roche Miditron	-	-	-	-	-	2	-	-
Roche Urisys	1	-	-	1	-	10	2	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	4	-	-
UriScan Reagent Strips	-	-	-	1	7	6	-	-

## URINALYSIS DIPSTICK–KETONES

### Specimen UA-2

<u>Method</u>	<i>Participant Results</i>				
	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHODS	1	-	-	3	133
Arkray Aution Jet	-	-	-	-	3
Arkray Aution Sticks	-	-	-	-	5
Arkray PocketChem UA	-	-	-	-	5
Bayer Clinitek 50	-	-	-	-	3
Bayer Clinitek 500	-	-	-	-	23
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	2
Bayer Reagent Strips	-	-	-	-	5
BioScan Reagent Strips	-	-	-	-	1
Quidel QuickVue UrinChek	-	-	-	-	1
Roche (BMC) Chemstrips	-	-	-	1	29
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	2
Roche Miditron	-	-	-	-	2
Roche Urisys	1	-	-	2	11
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	4
UriScan Reagent Strips	-	-	-	-	14

## URINALYSIS DIPSTICK–BILIRUBIN

### Specimen UA-2

<u>Method</u>	<i>Participant Results</i>			
	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	136	-	-	-
Arkray Aution Jet	3	-	-	-
Arkray Aution Sticks	5	-	-	-
Arkray PocketChem UA	4	-	-	-
Bayer Clinitek 50	3	-	-	-
Bayer Clinitek 500	23	-	-	-
Bayer Clinitek Atlas	5	-	-	-
Bayer Clinitek Status	2	-	-	-
Bayer Reagent Strips	4	-	-	-
BioScan Reagent Strips	1	-	-	-
Quidel QuickVue UrinChek	1	-	-	-
Roche (BMC) Chemstrips	31	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-
Roche (BMC) Mini UA	2	-	-	-
Roche Miditron	2	-	-	-
Roche Urisys	14	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-
UriScan Reagent Strips	14	-	-	-

**URINALYSIS DIPSTICK–UROBILINOGEN**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>&gt;8.0 mg/dL</u>
ALL METHODS	137	-	-	-	-
Arkray Aution Sticks	3	-	-	-	-
Arkray PocketChem UA	5	-	-	-	-
Bayer Clinitek 10 / 100	4	-	-	-	-
Bayer Clinitek 50	3	-	-	-	-
Bayer Clinitek 500	23	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	2	-	-	-	-
Bayer Reagent Strips	5	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	31	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Miditron	2	-	-	-	-
Roche Urisys	14	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Reagent Strips	14	-	-	-	-

**URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	2	-	2	12	122
Arkray Aution Sticks	-	-	-	-	3
Arkray PocketChem UA	-	-	-	4	1
Bayer Clinitek 10 / 100	-	-	1	1	3
Bayer Clinitek 50	-	-	-	-	3
Bayer Clinitek 500	-	-	-	-	23
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	2
Bayer Reagent Strips	-	-	-	-	5
BioScan Reagent Strips	-	-	-	-	1
Quidel QuickVue UrinChek	-	-	-	1	-
Roche (BMC) Chemstrips	-	-	-	-	31
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	2
Roche Miditron	-	-	-	-	2
Roche Urisys	1	-	-	-	13
Roche(BMC) SuperUA/ChemstripUA	1	-	-	-	3
UriScan Reagent Strips	-	-	-	1	13

**URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	134	-	-	-	2
Arkray Aution Sticks	3	-	-	-	-
Arkray PocketChem UA	5	-	-	-	-
Bayer Clinitek 10 / 100	5	-	-	-	-
Bayer Clinitek 50	3	-	-	-	-
Bayer Clinitek 500	23	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	2	-	-	-	-
Bayer Reagent Strips	5	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	30	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Mditron	2	-	-	-	-
Roche Urisys	13	-	-	-	1
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	1
UriScan Reagent Strips	14	-	-	-	-

**URINALYSIS DIPSTICK–NITRITE**

**Specimen UA-2**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	133	2
Arkray Aution Sticks	3	-
Arkray PocketChem UA	5	-
Bayer Clinitek 10 / 100	5	-
Bayer Clinitek 50	3	-
Bayer Clinitek 500	23	-
Bayer Clinitek Atlas	5	-
Bayer Clinitek Status	2	-
Bayer Reagent Strips	5	-
BioScan Reagent Strips	1	-
Quidel QuickVue UrinChek	1	-
Roche (BMC) Chemstrips	27	1
Roche (BMC) Criterion Analyzer	3	-
Roche (BMC) Mini UA	2	-
Roche Mditron	2	-
Roche Urisys	13	1
Roche(BMC) SuperUA/ChemstripUA	4	-
UriScan Reagent Strips	14	-

**URINALYSIS –MICROALBUMIN (dipstick only)****Specimen UA-2*****Participant Results***

<b><u>Method</u></b>	<b><u>Negative</u></b>	<b><u>10 mg/L(Pos)</u></b>	<b><u>20/30 mg/L</u></b>	<b><u>50 mg/L (+)</u></b>	<b><u>80 mg/L</u></b>	<b><u>100 mg/L (++)</u></b>	<b><u>150 mg/L</u></b>
ALL METHODS	1	-	-	-	1	4	4
Bayer Clinitek Microalbumin	-	-	-	-	-	-	1
Roche (BMC) Micral - 1 minute	-	-	-	-	-	1	-

**URINALYSIS –URINE hCG****Specimen UA-2*****Participant Results***

<b><u>Method</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>
ALL METHODS	13	1
Acon Laboratories	2	-
bioMerieux VIKIA hCG-D	6	-
Hybritech Icon II Serum/Urine	1	-

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Specimen SUS-6

<u>Antimicrobial</u>	-----Agar Diffusion-----				-----MIC-----				<u>Acceptable (%)</u>
	<u>Interpretative category data</u>				<u>Interpretative category data</u>				
	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	
Amikacin	9	9	-	-	29	29	-	-	100%
Amoxicillin/Clavulanate	5	4	-	1	27	27	-	-	95.83%
Ampicillin	7	5	-	2	37	36	-	1	95.65%
Ampicillin/Sulbactam	5	5	-	-	27	27	-	-	100%
Aztreonam	4	4	-	-	17	17	-	-	100%
Carbenicillin	2	2	-	-	1	1	-	-	100%
Cefazolin	1	1	-	-	26	26	-	-	100%
Cefepime	4	4	-	-	29	29	-	-	100%
Cefoperazone	2	2	-	-	1	1	-	-	100%
Cefotaxime	6	6	-	-	25	25	-	-	100%
Cefotetan	-	-	-	-	2	2	-	-	100%
Cefoxitin	1	1	-	-	5	5	-	-	100%
Ceftazidime	4	4	-	-	26	26	-	-	100%
Ceftriaxone	4	4	-	-	27	27	-	-	100%
Cefuroxime	2	2	-	-	27	27	-	-	100%
Cephalexin	1	1	-	-	2	1	-	1	Not graded <sup>1</sup>
Cephalothin	6	4	1	1	28	21	5	2	Not graded <sup>1</sup>
Ciprofloxacin	9	9	-	-	38	38	-	-	100%
Clindamycin	-	-	-	-	1	1	-	-	100%
Ertapenem	1	1	-	-	1	1	-	-	100%
Fosfomycin	2	2	-	-	2	2	-	-	100%
Gatifloxacin	-	-	-	-	3	3	-	-	100%
Gentamicin	8	8	-	-	37	37	-	-	100%
Imipenem	4	4	-	-	29	29	-	-	100%
Levofloxacin	1	1	-	-	24	24	-	-	94.59%
Meropenem	3	3	-	-	8	8	-	-	100%
Nalidixic Acid	4	4	-	-	7	7	-	-	100%
Netilmicin	1	1	-	-	1	1	-	-	100%
Nitrofurantoin	11	11	-	-	31	31	-	-	100%
Norfloxacin	8	8	-	-	9	9	-	-	100%
Ofloxacin	-	-	-	-	3	3	-	-	100%
Oxacillin	-	-	-	-	2	-	-	2	100%
Penicillin	4	1	-	3	1	-	-	1	80%
Piperacillin	1	1	-	-	10	10	-	-	100%
Piperacillin/Tazobactam	2	2	-	-	29	29	-	-	100%
Rifampin	-	-	-	-	1	-	-	1	100%
Tetracycline	1	1	-	-	16	16	-	-	100%
Ticarcillin	2	2	-	-	3	3	-	-	100%
Ticarcillin/Clavulanate	-	-	-	-	22	1	-	-	95.65%
Tobramycin	-	-	-	-	27	27	-	-	100%
Trimethoprim	-	-	-	-	12	12	-	-	100%
Trimethoprim/Sulfamethoxazole	11	11	-	-	37	36	-	1	98.70%
Vancomycin	2	1	-	1	1	-	-	1	Not graded <sup>1</sup>

Organism present in specimen SUS-6: *Escherichia coli*.

<sup>1</sup> This is an ungraded challenge due to less than 80% participant consensus.

## PARASITOLOGY (PA Specimens)

### Specimen PA-6

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	1	100%	Unacceptable

Parasite present in specimen PA-6: *Entamoeba histolytica*. Rare *Blastocystis hominis* seen.

### Specimen PA-7

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Other parasite seen but no ID	1	100%	Acceptable

Parasite present in specimen PA-7: *Endolimax nana*. Rare *Blastocystis hominis* seen.

### Specimen PA-8

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	1	50.00%	Acceptable
Ascaris lumbricoides eggs	1	50.00%	

Parasite present in specimen PA-8: No parasites present.

### Specimen PA-9

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Taenia sp. eggs	1	50.00%	Acceptable
Hymenolepis nana eggs	1	50.00%	

Parasite present in specimen PA-9: *Taenia sp.* Eggs. Small numbers of *Giardia lamblia* cysts are also present.

### Specimen PA-10

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	1	50.00%	Acceptable
No parasite seen	1	50.00%	

Parasites present in specimen PA-10: *Ascaris lumbricoides* eggs, *Blastocystis hominis*, *Endolimax nana* and *Cryptosporidium sp.*

## PARASITOLOGY (FP Specimens)

### Specimen FP-6

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Strongyloides stercoralis larvae	83	74.77%	Acceptable
Parasite larva seen but no ID	5	4.50%	Acceptable
No parasite seen	11	9.91%	
Endolimax nana	4	3.60%	
Schistosoma japonicum eggs	3	2.70%	
Sarcocystis sp. oocysts	2	1.80%	
Parasite egg seen but no ID	1	0.90%	
Giardia lamblia	1	0.90%	
Iodamoeba butschlii	1	0.90%	

Parasite present in specimen FP-6: *Strongyloides stercoralis* larvae.

### Specimen FP-7

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Endolimax nana	88	78.57%	Acceptable
No parasite seen	12	10.71%	
Blastocystis hominis	4	3.57%	
Entamoeba histolytica	2	1.79%	
Strongyloides stercoralis larvae	2	1.79%	
Hookworm	1	0.89%	
Hymenolepis nana eggs	1	0.89%	
Chilomastix mesnili	1	0.89%	
Cryptosporidium sp., oocysts	1	0.89%	

Parasite present in specimen FP-7: *Endolimax nana*.

### Specimen FP-8

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	96	73.85%	Acceptable
Blastocystis hominis	19	14.62%	Acceptable
Endolimax nana	2	1.54%	Acceptable
No parasite seen	7	5.38%	
Hookworm	2	1.54%	
Entamoeba coli	1	0.77%	
Entamoeba histolytica	1	0.77%	
Taenia sp. eggs	1	0.77%	
Nonpath. protozoan present	1	0.77%	

Parasites present in specimen FP-8: *Ascaris lumbricoides* eggs, *Blastocystis hominis*, and *Endolimax nana*. *Cryptosporidium* also seen.

**PARASITOLOGY (FP Specimens)**

**Specimen FP-9**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Taenia sp. eggs	92	71.32%	Acceptable
Giardia lamblia	14	10.85%	Acceptable
Hymenolepis diminuta eggs	4	3.10%	
No parasite seen	4	3.10%	
Chilomastix mesnili	4	3.10%	
Hymenolepis nana eggs	3	2.33%	
Hookworm	3	2.33%	
Endolimax nana	2	1.55%	
Ascaris lumbricoides eggs	1	0.78%	
Blastocystis hominis	1	0.78%	
Isospora belli oocysts	1	0.78%	

Parasites present in specimen FP-9: *Taenia sp. eggs* and *Giardia lamblia*.

**Specimen FP-10**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	73	71.57%	Acceptable
Plasmodium falciparum	8	7.84%	
Plasmodium sp., NOS	7	6.86%	
Leishmania sp.	6	5.88%	
Babesia sp.	2	1.96%	
Plasmodium vivax	2	1.96%	
Toxoplasma gondii	1	0.98%	
Trypanosoma sp., NOS	1	0.98%	
Plasmodium malariae	1	0.98%	
Plasmodium ovale	1	0.98%	

Parasite present in specimen FP-10: No parasite present.

**Syphilis Serology—Qualitative: VDRL Slide**

<u>Method</u>	<u>Specimen SY-6</u>			<u>Specimen SY-7</u>			<u>Specimen SY-8</u>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	-	7	3	-	4	4	1	2
BioBacter	-	-	1	-	-	1	-	-	1
bioMerieux	-	-	1	-	-	1	-	-	1
Wiener Lab	-	-	4	3	-	1	4	-	-
<u>Method</u>	<u>Specimen SY-9</u>			<u>Specimen SY-10</u>					
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>			
ALL METHODS	4	2	1	1	-	6			
BioBacter	-	1	-	-	-	1			
bioMerieux	-	1	-	-	-	1			
Wiener Lab	4	-	-	1	-	3			

**Syphilis Serology—Quantitative: VDRL Slide Titer**

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>&gt;32 dils</u>
<b>Specimen SY-7</b>								
ALL METHODS	2	-	1	-	-	-	-	-
BioBacter	-	-	-	-	-	-	-	-
Wiener Lab	2	-	1	-	-	-	-	-
<b>Specimen SY-8</b>								
ALL METHODS	2	-	2	-	-	-	-	-
BioBacter	-	-	-	-	-	-	-	-
Wiener Lab	2	-	2	-	-	-	-	-
<b>Specimen SY-9</b>								
ALL METHODS	2	1	3	-	-	-	-	-
BioBacter	1	-	-	-	-	-	-	-
bioMerieux	1	-	-	-	-	-	-	-
Wiener Lab	-	1	3	-	-	-	-	-

**Syphilis Serology—Qualitative: MHA-TP**

<u>Method</u>	<u>Specimen SY-6</u>		<u>Specimen SY-7</u>		<u>Specimen SY-8</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	9	9	-	9	-
Bio-Rad Evolis	-	1	1	-	1	-
Human	-	1	1	-	1	-
Serodia	-	3	3	-	3	-
<u>Method</u>	<u>Specimen SY-9</u>		<u>Specimen SY-10</u>			
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>		
ALL METHODS	7	2	-	9		
Bio-Rad Evolis	1	-	-	1		
Human	-	1	-	1		
Serodia	3	-	-	3		

**Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)**

<u>Method</u>	<u>Specimen SY-6</u>		<u>Specimen SY-7</u>		<u>Specimen SY-8</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	6	6	-	6	-
bioMerieux	-	2	2	-	2	-
<u>Method</u>	<u>Specimen SY-9</u>		<u>Specimen SY-10</u>			
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>		
ALL METHODS	6	-	-	6		
bioMerieux	2	-	-	2		

**Syphilis Serology—Qualitative: RPR**

<b><u>Method</u></b>	<b>Specimen SY-6</b>		<b>Specimen SY-7</b>		<b>Specimen SY-8</b>	
	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>	<b><u>Reactive</u></b>	<b><u>Non-Reactive</u></b>
ALL METHODS	2	22	21	3	22	2
Abbott Syfacard-R	-	2	2	-	2	-
Becton Dickinson	-	3	3	-	3	-
BioBacter	-	1	-	1	-	1
bioMerieux	-	4	2	2	3	1
Immunostics Inc.	-	1	1	-	1	-
Omega Diagnostics	1	3	4	-	4	-
SPINREACT	-	4	4	-	4	-
Wiener Lab	-	1	1	-	1	-

  

	<b>Specimen SY-9</b>		<b>Specimen SY-10</b>	
ALL METHODS	24	-	1	23
Abbott Syfacard-R	2	-	-	2
Becton Dickinson	3	-	-	3
BioBacter	1	-	-	1
bioMerieux	4	-	-	4
Immunostics Inc.	1	-	-	1
Omega Diagnostics	4	-	1	3
SPINREACT	4	-	-	4
Wiener Lab	1	-	-	1

**Syphilis Serology—Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>&gt;64</u>
<b>Specimen SY-7</b>								
ALL METHODS	8	5	-	-	1	-	-	-
Abbott Syfacard-R	1	1	-	-	-	-	-	-
BioBacter	-	-	-	-	-	-	-	-
bioMerieux	2	-	-	-	-	-	-	-
Omega Diagnostics	-	2	-	-	1	-	-	-
SPINREACT	3	1	-	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-
<b>Specimen SY-8</b>								
ALL METHODS	7	6	1	-	1	-	-	-
Abbott Syfacard-R	1	1	-	-	-	-	-	-
BioBacter	-	-	-	-	-	-	-	-
bioMerieux	2	1	-	-	-	-	-	-
Omega Diagnostics	-	2	-	-	1	-	-	-
SPINREACT	2	1	1	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-
<b>Specimen SY-9</b>								
ALL METHODS	2	9	4	1	-	1	-	-
Abbott Syfacard-R	-	2	-	-	-	-	-	-
BioBacter	1	-	-	-	-	-	-	-
bioMerieux	-	3	-	1	-	-	-	-
Omega Diagnostics	-	-	2	-	-	1	-	-
SPINREACT	-	2	2	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-

**Viral Markers – Anti-HBc**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	42	-	42	-	42
Abbott Architect	-	4	-	4	-	4
Abbott Architect - IgG	-	1	-	1	-	1
Abbott AxSYM	-	2	-	2	-	2
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	10	-	10	-	10
Bayer ADVIA Centaur	-	1	-	1	-	1
Beckman ACCESS	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
Bio-Rad Evolis	-	2	-	2	-	2
DiaSorin	-	1	-	1	-	1
Other IgG Method	-	2	-	2	-	2
Other Total Method	-	3	-	3	-	3
Roche Elecsys - IgM	-	1	-	1	-	1
Roche Elecsys 1010/2010	-	4	-	4	-	4
Roche Modular Analytics	-	1	-	1	-	1
VITROS ECI	-	4	-	4	-	4
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	39	3	1	41		
Abbott Architect	4	-	-	4		
Abbott Architect - IgG	1	-	-	1		
Abbott AxSYM	2	-	-	2		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	10	-	-	10		
Bayer ADVIA Centaur	1	-	-	1		
Beckman ACCESS	1	-	-	1		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
Bio-Rad Evolis	2	-	-	2		
DiaSorin	1	-	-	1		
Other IgG Method	2	-	-	2		
Other Total Method	3	-	-	3		
Roche Elecsys - IgM	-	1	-	1		
Roche Elecsys 1010/2010	4	-	-	4		
Roche Modular Analytics	1	-	1	-		
VITROS ECI	4	-	-	4		

**Viral Markers – Anti-HIV**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	51	1	-	52	52	-
Abbott Architect	6	-	-	6	6	-
Abbott AxSYM	2	-	-	2	2	-
Abbott AxSYM - IgM	1	-	-	1	1	-
Abbott AxSYM - Total	12	-	-	12	12	-
Bayer ADVIA Centaur	2	-	-	2	2	-
Beckman ACCESS	1	-	-	1	1	-
bioMerieux Vidas - IgM	2	-	-	2	2	-
bioMerieux Vitek, Mini Vidas	1	-	-	1	1	-
Bio-Rad Evolis	2	-	-	2	2	-
Other IgG Method	1	-	-	1	1	-
Other IgM method	1	-	-	1	1	-
Other Total Method	8	-	-	8	8	-
Roche Elecsys 1010/2010	9	-	-	9	9	-
Roche Modular Analytics	1	-	-	1	1	-
VITROS ECI	1	-	-	1	1	-
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	1	50	-	52		
Abbott Architect	1	5	-	6		
Abbott AxSYM	-	2	-	2		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	11	-	12		
Bayer ADVIA Centaur	-	2	-	2		
Beckman ACCESS	-	1	-	1		
bioMerieux Vidas - IgM	-	2	-	2		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
Bio-Rad Evolis	-	2	-	2		
Other IgG Method	-	1	-	1		
Other IgM method	-	1	-	1		
Other Total Method	-	8	-	8		
Roche Elecsys 1010/2010	-	9	-	9		
Roche Modular Analytics	-	1	-	1		
VITROS ECI	-	1	-	1		

**Viral Markers – HAV**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	36	1	36	1	36
Abbott Architect	-	1	-	1	-	1
Abbott Architect - IgG	-	2	-	2	-	2
Abbott AxSYM	-	3	-	3	-	3
Abbott AxSYM - IgM	-	4	-	4	-	4
Abbott AxSYM - Total	-	5	-	5	1	4
Bayer ADVIA Centaur	-	1	1	-	-	1
bioMerieux Vidas - IgM	-	4	-	4	-	4
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin	-	1	-	1	-	1
Other IgG Method	-	2	-	2	-	2
Other Total Method	-	2	-	2	-	2
Roche Elecsys - IgM	-	4	-	4	-	4
Roche Elecsys 1010/2010	-	4	-	5	-	5
Roche Modular Analytics	-	1	-	1	-	1

  

	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>	
ALL METHODS	-	37	-	37
Abbott Architect	-	1	-	1
Abbott Architect - IgG	-	2	-	2
Abbott AxSYM	-	3	-	3
Abbott AxSYM - IgM	-	4	-	4
Abbott AxSYM - Total	-	5	-	5
Bayer ADVIA Centaur	-	1	-	1
bioMerieux Vidas - IgM	-	4	-	4
bioMerieux Vitek, Mini Vidas	-	1	-	1
DiaSorin	-	1	-	1
Other IgG Method	-	2	-	2
Other Total Method	-	2	-	2
Roche Elecsys - IgM	-	4	-	4
Roche Elecsys 1010/2010	-	5	-	5
Roche Modular Analytics	-	1	-	1

**Viral Markers – HBeAg**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	20	-	20	-	20
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - Total	-	6	-	6	-	6
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin	-	1	-	1	-	1
Omega Diagnostics	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Other Total Method	-	2	-	2	-	2
Roche Elecsys 1010/2010	-	2	-	2	-	2
Roche Modular Analytics	-	1	-	1	-	1
VITROS Eci	-	1	-	1	-	1
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	3	17	-	19		
Abbott AxSYM	-	1	-	1		
Abbott AxSYM - Total	1	5	-	5		
bioMerieux Vidas - IgM	1	-	-	1		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
DiaSorin	-	1	-	1		
Omega Diagnostics	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	-	2	-	2		
Roche Elecsys 1010/2010	-	2	-	2		
Roche Modular Analytics	-	1	-	1		
VITROS Eci	-	1	-	1		

**Viral Markers – HBsAb**

<b><u>Method</u></b>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	1	35	2	35	-	37
Abbott Architect	-	3	-	3	-	3
Abbott AxSYM	-	4	-	4	-	4
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	6	-	6	-	6
Bayer ADVIA Centaur	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin	-	1	-	1	-	1
Other IgG Method	1	1	1	1	-	2
Other Method Specified	-	1	-	1	-	1
Other Total Method	-	4	-	4	-	4
Roche Elecsys 1010/2010	-	7	1	7	-	8
Roche Modular Analytics	-	1	-	1	-	1
VITROS ECi	-	2	-	2	-	2
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	2	33	3	34		
Abbott Architect	-	3	-	3		
Abbott AxSYM	-	4	1	3		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	6	-	6		
Bayer ADVIA Centaur	1	-	-	1		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
DiaSorin	-	1	-	1		
Other IgG Method	-	2	1	1		
Other Method Specified	-	-	-	1		
Other Total Method	1	3	-	4		
Roche Elecsys 1010/2010	-	7	1	7		
Roche Modular Analytics	-	1	-	1		
VITROS ECi	-	2	-	2		

**Viral Markers – Anti-HBsAg**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	54	1	-	55	54	1
Abbott Architect	6	-	-	6	6	-
Abbott AxSYM	2	-	-	2	2	-
Abbott AxSYM - IgM	1	-	-	1	1	-
Abbott AxSYM - Total	11	-	-	11	11	-
Bayer ADVIA Centaur	2	-	-	2	2	-
Beckman ACCESS	1	-	-	1	1	-
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	1	-	-	1	1	-
Bio-Rad Evolis	2	-	-	2	2	-
DiaSorin	1	-	-	1	1	-
Omega Diagnostics	1	-	-	1	1	-
Other IgG Method	2	-	-	2	2	-
Other Total Method	7	-	-	7	7	-
Roche Elecsys 1010/2010	9	-	-	9	9	-
Roche Modular Analytics	1	-	-	1	1	-
VITROS ECI	4	-	-	4	4	-
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	52	3	-	55		
Abbott Architect	6	-	-	6		
Abbott AxSYM	2	-	-	2		
Abbott AxSYM - IgM	1	-	-	1		
Abbott AxSYM - Total	10	1	-	11		
Bayer ADVIA Centaur	2	-	-	2		
Beckman ACCESS	1	-	-	1		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
Bio-Rad Evolis	2	-	-	2		
DiaSorin	1	-	-	1		
Omega Diagnostics	-	1	-	1		
Other IgG Method	2	-	-	2		
Other Total Method	7	-	-	7		
Roche Elecsys 1010/2010	9	-	-	9		
Roche Modular Analytics	1	-	-	1		
VITROS ECI	4	-	-	4		

**Viral Markers – HCV**

<u>Method</u>	<b>Specimen VM-6</b>		<b>Specimen VM-7</b>		<b>Specimen VM-8</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	44	-	44	-	43
Abbott Architect	-	4	-	4	-	4
Abbott Architect - IgG	-	1	-	1	-	1
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	12	-	12	-	12
Abbott IMx	-	1	-	1	-	1
Acon Laboratories	-	1	-	1	-	1
Bayer ADVIA Centaur	-	3	-	3	-	3
Bio-Rad Evolis	-	2	-	2	-	2
Dade Behring BEP 2000	-	1	-	1	-	1
Omega Diagnostics	-	1	-	1	-	1
Other IgG Method	-	2	-	2	-	2
Other Total Method	-	8	-	8	-	7
VITROS ECi	-	4	-	4	-	4
VITROS ECi - IgM	-	1	-	1	-	1
	<b>Specimen VM-9</b>		<b>Specimen VM-10</b>			
ALL METHODS	-	43	-	43		
Abbott Architect	-	4	-	4		
Abbott Architect - IgG	-	1	-	1		
Abbott AxSYM	-	1	-	1		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	12	-	12		
Abbott IMx	-	1	-	1		
Acon Laboratories	-	1	-	1		
Bayer ADVIA Centaur	-	3	-	3		
Bio-Rad Evolis	-	2	-	2		
Dade Behring BEP 2000	-	1	-	1		
Omega Diagnostics	-	1	-	1		
Other IgG Method	-	2	-	2		
Other Total Method	-	7	-	7		
VITROS ECi	-	4	-	4		
VITROS ECi - IgM	-	1	-	1		

## Blood Gases – pH

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	7.167	0.016	0.2	7.17	29	6.888	0.030	0.4	6.89
AVL OMNI	12	7.168	0.010	0.1	7.17	13	6.902	0.015	0.2	6.90
Chiron Diagnostics 248	5	7.180	0.012	0.2	7.18	5	6.886	0.023	0.3	6.88

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	29	7.154	0.020	0.3	7.15	29	7.563	0.020	0.3	7.56
AVL OMNI	13	7.153	0.008	0.1	7.15	13	7.554	0.009	0.1	7.55
Chiron Diagnostics 248	5	7.174	0.009	0.1	7.18	5	7.584	0.023	0.3	7.59

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	7.781	0.030	0.4	7.77
AVL OMNI	13	7.767	0.012	0.2	7.77
Chiron Diagnostics 248	5	7.804	0.035	0.4	7.80

## Blood Gases - pCO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	29	70.41	2.65	3.8	70.4	29	89.57	6.54	7.3	89.8
AVL OMNI	13	70.41	2.55	3.6	71.4	13	87.79	3.33	3.8	88.2
Chiron Diagnostics 248	5	70.52	1.42	2.0	70.4	5	92.40	2.17	2.4	92.4

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	29	73.39	2.57	3.5	73.0	29	23.33	1.57	6.7	23.2
AVL OMNI	13	73.42	1.95	2.6	73.0	13	23.41	0.68	2.9	23.5
Chiron Diagnostics 248	5	71.80	1.52	2.1	72.6	5	21.40	0.56	2.6	21.6

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	27	12.81	1.13	8.8	12.9
AVL OMNI	13	12.98	0.68	5.2	12.9
Chiron Diagnostics 248	5	11.38	0.37	3.3	11.5

## Blood Gases - pO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-6					Specimen BG-7				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	29	71.43	9.13	12.8	71.0	29	40.73	16.95	41.6	43.8
AVL OMNI	13	76.15	10.57	13.9	79.7	12	53.55	5.38	10.1	53.6
Chiron Diagnostics 248	5	66.56	4.22	6.3	64.6	5	25.30	3.10	12.3	25.3

<u>Method</u>	Specimen BG-8					Specimen BG-9				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	29	71.09	9.40	13.2	71.0	29	142.16	14.31	10.1	142.2
AVL OMNI	12	79.07	4.22	5.3	80.6	13	139.36	7.70	5.5	140.1
Chiron Diagnostics 248	5	61.80	3.03	4.9	59.8	5	144.76	7.45	5.1	146.8

<u>Method</u>	Specimen BG-10				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	27	459.36	34.10	7.4	458.0
AVL OMNI	13	447.35	36.67	8.2	440.6
Chiron Diagnostics 248	5	462.70	11.10	2.4	464.2

**Blood Gases - Ionized Calcium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-6</u>				<u>Specimen BG-7</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	1.413	0.059	4.2	1.42	7	2.547	0.714	28.0	2.61

**Blood Gases - Chloride (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-6</u>				<u>Specimen BG-7</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	5	79.4	4.4	5.5	78	6	66.7	3.1	4.7	66
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-8</u>				<u>Specimen BG-9</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	5	78.2	4.1	5.3	76	8	118.6	4.0	3.4	120
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-10</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	129.0	3.9	3.0	128					

**Blood Gases - Potassium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-6</u>				<u>Specimen BG-7</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	1.82	0.09	5.0	1.8	7	11.36	0.36	3.1	11.2
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-8</u>				<u>Specimen BG-9</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	1.84	0.10	5.3	1.9	10	6.30	0.18	2.8	6.3
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-10</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	1.58	0.11	7.2	1.6					

**Blood Gases - Sodium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-6</u>				<u>Specimen BG-7</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	112.4	2.4	2.1	113	8	86.5	2.5	2.9	86
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-8</u>				<u>Specimen BG-9</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	10	111.1	2.1	1.9	112	8	155.1	1.4	0.9	156
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-10</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	9	165.4	2.5	1.5	166					

**Medical Laboratory Evaluation**  
 2011 Pennsylvania Avenue, NW, Suite 800  
 Washington, DC 20006-1813  
 800-338-2746 • 202-261-4500 • Fax: 202-835-0440  
[www.acponline.org/mle](http://www.acponline.org/mle)